CA3188387A1 - Compositions and methods for treating or preventing disease associated with beta coronavirus infection - Google Patents
Compositions and methods for treating or preventing disease associated with beta coronavirus infectionInfo
- Publication number
- CA3188387A1 CA3188387A1 CA3188387A CA3188387A CA3188387A1 CA 3188387 A1 CA3188387 A1 CA 3188387A1 CA 3188387 A CA3188387 A CA 3188387A CA 3188387 A CA3188387 A CA 3188387A CA 3188387 A1 CA3188387 A1 CA 3188387A1
- Authority
- CA
- Canada
- Prior art keywords
- ketotifen
- nsaid
- subject
- administered
- indomethacin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063062138P | 2020-08-06 | 2020-08-06 | |
| US63/062,138 | 2020-08-06 | ||
| PCT/US2021/044897 WO2022032069A1 (en) | 2020-08-06 | 2021-08-06 | Compositions and methods for treating or preventing disease associated with beta coronavirus infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3188387A1 true CA3188387A1 (en) | 2022-02-10 |
Family
ID=80117684
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3188387A Pending CA3188387A1 (en) | 2020-08-06 | 2021-08-06 | Compositions and methods for treating or preventing disease associated with beta coronavirus infection |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240033259A1 (https=) |
| EP (1) | EP4192457B1 (https=) |
| JP (1) | JP2023537369A (https=) |
| KR (1) | KR20230048517A (https=) |
| CN (1) | CN116322662A (https=) |
| AU (1) | AU2021321535A1 (https=) |
| CA (1) | CA3188387A1 (https=) |
| IL (1) | IL300406A (https=) |
| MX (1) | MX2023001570A (https=) |
| WO (1) | WO2022032069A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116178373A (zh) * | 2022-12-06 | 2023-05-30 | 南方科技大学 | 非甾体抗炎药和gs-441524的二联体化合物及其制备方法与用途 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019046201A1 (en) | 2017-08-30 | 2019-03-07 | SEN-JAM Pharmaceutical LLC | METHODS AND COMPOSITIONS FOR INHIBITING ADVERSE REACTIONS ASSOCIATED WITH VACCINATION |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180360811A1 (en) * | 2017-06-16 | 2018-12-20 | SEN-JAM Pharmaceutical LLC | Methods and Compositions to Inhibit Symptoms Associated with Viral Upper Respiratory Tract Infections |
| WO2019046201A1 (en) * | 2017-08-30 | 2019-03-07 | SEN-JAM Pharmaceutical LLC | METHODS AND COMPOSITIONS FOR INHIBITING ADVERSE REACTIONS ASSOCIATED WITH VACCINATION |
-
2021
- 2021-08-06 MX MX2023001570A patent/MX2023001570A/es unknown
- 2021-08-06 JP JP2023508084A patent/JP2023537369A/ja active Pending
- 2021-08-06 AU AU2021321535A patent/AU2021321535A1/en active Pending
- 2021-08-06 CN CN202180068018.3A patent/CN116322662A/zh active Pending
- 2021-08-06 WO PCT/US2021/044897 patent/WO2022032069A1/en not_active Ceased
- 2021-08-06 US US18/019,959 patent/US20240033259A1/en active Pending
- 2021-08-06 EP EP21853813.0A patent/EP4192457B1/en active Active
- 2021-08-06 KR KR1020237006880A patent/KR20230048517A/ko active Pending
- 2021-08-06 IL IL300406A patent/IL300406A/en unknown
- 2021-08-06 CA CA3188387A patent/CA3188387A1/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116178373A (zh) * | 2022-12-06 | 2023-05-30 | 南方科技大学 | 非甾体抗炎药和gs-441524的二联体化合物及其制备方法与用途 |
| CN116178373B (zh) * | 2022-12-06 | 2024-06-18 | 南方科技大学 | 非甾体抗炎药和gs-441524的二联体化合物及其制备方法与用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4192457A1 (en) | 2023-06-14 |
| AU2021321535A1 (en) | 2023-03-23 |
| IL300406A (en) | 2023-04-01 |
| EP4192457A4 (en) | 2024-09-18 |
| MX2023001570A (es) | 2023-05-03 |
| CN116322662A (zh) | 2023-06-23 |
| WO2022032069A1 (en) | 2022-02-10 |
| KR20230048517A (ko) | 2023-04-11 |
| JP2023537369A (ja) | 2023-08-31 |
| EP4192457B1 (en) | 2026-03-25 |
| US20240033259A1 (en) | 2024-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20150018396A1 (en) | Prevention and treatment of respiratory infection with peroxisome proliferator activator receptor delta agonist | |
| US11135202B2 (en) | Thiazolide compounds for treating viral infections | |
| EP3551187B1 (en) | Nintedanib for use in methods for the treatment of interstitial lung diseases by coadministration with olodaterol | |
| EP2799071A1 (en) | Levocetirizine and montelukast for the treatment of influenza, common cold and inflammation | |
| TW202532084A (zh) | 瑞德西韋之治療方法 | |
| US20240033259A1 (en) | Compositions and methods for treating or preventing disease associated with beta coronavirus infection | |
| US20210322404A1 (en) | Fgfr regulation for the treatment of viral infections | |
| JP2023510719A (ja) | コロナウイルス感染症の治療方法 | |
| MX2012014334A (es) | Tratamiento de diabetes tipo 2. | |
| US20240115559A1 (en) | Methods and Compositions to Inhibit Symptoms Associated with Viral Upper Respiratory Tract Infections | |
| US20230226066A1 (en) | Compounds for the treatment of viral infections | |
| RU2237475C1 (ru) | Комбинированный препарат для устранения симптомов простудных заболеваний и гриппа (варианты) | |
| US20250375398A1 (en) | Combination therapies for the treatment of viral infections | |
| US20230241037A1 (en) | Cross-linked medication for treatment of coronaviral infection and method of treatment | |
| US20240165099A1 (en) | Methods for the treatment and prevention of diseases or infections with mcp-1 involvement by administration of tafenoquine | |
| US20250205268A1 (en) | Treatment of viruses with antiviral nucleosides | |
| US20230301991A1 (en) | Compounds for the treatment of viral infections | |
| JP2025504519A (ja) | Ｓａｒｓ－ｃｏｖ－２に起因する感染症の予防および／または処置における使用のための化合物 | |
| US20230141355A1 (en) | Cxcl8 inhibitors for use in the treatment of covid-19 | |
| CN118079003A (zh) | 用于降低尿酸水平的磷酸二酯酶5型抑制剂及其用途 | |
| EA050990B1 (ru) | Применение нуклеозидного соединения при лечении коронавирусных инфекционных заболеваний | |
| CN117838689A (zh) | 培菲替尼在制备治疗流感病毒感染的药物中的应用 | |
| CN117100724A (zh) | 白藜芦醇及其类似物在制备治疗单纯疱疹病毒性脑炎药物中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240723 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240723 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240723 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250805 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250805 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250805 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250805 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250805 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250807 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251104 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20251104 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251104 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251104 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251105 |